ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2025 Financial Results and Participation at Upcoming Conferences

Company Overview - ARS Pharmaceuticals, Inc. is a biopharmaceutical company focused on empowering at-risk patients and their caregivers to protect against allergic reactions that could lead to anaphylaxis [3] Upcoming Events - The company will host a conference call and webcast on March 9, 2026, at 5:30 a.m. PT / 8:30 a.m. ET to discuss its fourth quarter and full year 2025 financial results and business highlights [1] - ARS Pharma Management will participate in several upcoming investor conferences, including the 10th Annual Oppenheimer Emerging Growth Conference on February 25, 2026, and the Leerink Conference on March 11, 2026 [4] Product Information - ARS Pharmaceuticals is commercializing neffy® (trade name EURneffy® in the EU and 优敏速® in China), an epinephrine nasal spray for emergency treatment of Type I allergic reactions, including anaphylaxis, in adults and pediatric patients aged 4 years and older who weigh 33 lbs. or greater in the U.S. [3] - In the EU, neffy® is indicated for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens, as well as idiopathic or exercise-induced anaphylaxis in adults and children who weigh 30 kg or greater [3]